The science does not yet support regulatory approval of amyloid-targeting therapies for Alzheimer's disease based solely on biomarker evidence.

Planche V, Schindler S, Knopman DS, Frisoni G, Galasko D, Grill JD, Schneider L, Karlawish J, Villain N

DOI: 10.1002/alz.70068
Published: 2025 Apr
Container: Alzheimer's & dementia : the journal of the Alzheimer's Association
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/alz.70068,
  title = {The science does not yet support regulatory approval of amyloid-targeting therapies for Alzheimer's disease based solely on biomarker evidence.},
  author = {Planche V and Schindler S and Knopman DS and Frisoni G and Galasko D and Grill JD and Schneider L and Karlawish J and Villain N},
  year = {2025},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  doi = {10.1002/alz.70068},
  url = {https://doi.org/10.1002/alz.70068}
}

RIS

TY  - JOUR
TI  - The science does not yet support regulatory approval of amyloid-targeting therapies for Alzheimer's disease based solely on biomarker evidence.
AU  - Planche V
AU  - Schindler S
AU  - Knopman DS
AU  - Frisoni G
AU  - Galasko D
AU  - Grill JD
AU  - Schneider L
AU  - Karlawish J
AU  - Villain N
PY  - 2025
JO  - Alzheimer's & dementia : the journal of the Alzheimer's Association
DO  - 10.1002/alz.70068
UR  - https://doi.org/10.1002/alz.70068
ER  -

APA

V, P., S, S., DS, K., G, F., D, G., JD, G., L, S., J, K., & N, V. (2025). The science does not yet support regulatory approval of amyloid-targeting therapies for Alzheimer's disease based solely on biomarker evidence.. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.70068

Source records

pubmed · retrieved 2026-09-26T06:23:27.447Z